Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug Development

Suzhou Ribo Life Science Co., Ltd. ("Ribo " or the "Company") announced that its international R&D center - Ribocure Pharmaceuticals AB - has successfully completed an equity financing of USD33 million.

This round was led by renowned Swedish investor Mr. Erik Selin, with follow-on investment from Mr. Jacob Torell,  GoCo Health Innovation City in Gothenburg, Sweden. Upon completion, Mr. Erik Selin joined the board of Ribocure. The closing of this financing round represents another critical milestone in Ribo’s global expansion, demonstrating strong recognition by international capital for the global strategy of China's innovative drug development.

Dr. Gan Liming, Co-CEO and President of Global R&D, said: "We are honored to welcome Erik and Jacob as strategic investors to Ribocure. Their expertise and industry resources will significantly advance our development of innovative therapies for patients worldwide."

Mr. Zhang Su, CFO and Board Secretary, said: "Ribo's previous financing rounds received strong support from leading domestic institutions. The close of Ribocure’s financing marks a milestone in our global resource allocation, heralding a new development phase for Ribo."

Dr. Liang Zicai, Chairman & CEO, said: "In the global pharmaceutical innovation landscape, globalization has become the core competitiveness of Chinese biotech companies. By deeply integrating domestic R&D strengths with international expertise, Ribo has established a world-class siRNA drug development platform, providing robust support for our global market competitiveness."